Symptom Identification and Management in Patiens With Hematological Malignacy - A Randomized Controlled Trial Using HM-PRO
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hematologic Malignancy
- Sponsor
- Rigshospitalet, Denmark
- Enrollment
- 94
- Locations
- 1
- Primary Endpoint
- Change in Health related quality og life: EORTC QLQ C30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The aim is to study the effect of a systematic approach to symptom identification and management with disease specific and clinically developed PRO (HM-PRO) with a 12 month follow up in outpatient care in patients with chronic hematological malignancy.
Detailed Description
Design: A two-arm prospective randomized controlled trial. Population: Patients diagnosed with chronic myeloid leukemia (CML), clonal cytopenia of unknown significance (CCUS), myelodysplastic syndrome (MDS) or myeloproliferative neoplasia (MPN). Patients will be recruited from the outpatient clinic at the Dept. of Hematology at Rigshospitalet in Denmark. Patients will be identified and screened by their physician. Patients who are eligible for study inclusion will hereafter be approached, informed and recruited by the primary research investigator. Included patients will be randomized and allocated 1:1 to an intervention group or a control group. The intervention group will have a predetermined consultation appointment planned to assess medical status and symptom control. Seven days prior to the scheduled visit, the patient will receive an electronic invitation via RedCap to complete and send PRO data (HM-PRO). Prior to each appointment PRO data will be evaluated by a nurse from an algorithm deciding one of three tracks for the patients. The control group will receive standard care in the outpatient clinic. The patient has a predetermined consultation appointment at the hospital one time a year with a doctor to evaluate medical status and symptom control. Data Collection: The questionnaires will be distributed and completed by patients electronically via REDCap consisting of clinical data, PRO data (HM-PRO) and endpoint measures (see below). * Primary outcome: Change in QoL measured by EORTC-QLQ-C30, global health domain, at 12 months. * Secondary outcomes: Change in symptoms of depression and anxiety measured by HADS, change in symptom burden measured by MDASI symptom scale and clinical data outcomes at 12 months.
Investigators
Mary Jarden
Professor
Rigshospitalet, Denmark
Eligibility Criteria
Inclusion Criteria
- •adults \> 18 years
- •diagnosed and undergoing follow up for a hematological malignancy in the outpatient clinic, Rigshospitalet
- •The patients can be included approximately six months after initial diagnosis if in stable condition.
- •able to manage an e-mail account
Exclusion Criteria
- •Patients who do not understand, read and speak Danish and/or have cognitive/psychiatric disorders not compatible with inclusion in a clinical study.
Outcomes
Primary Outcomes
Change in Health related quality og life: EORTC QLQ C30
Time Frame: At 12 months
The global health domain
Secondary Outcomes
- Changes in symptoms of depression and anxiety measured by HADS(6 and 12 months)
- Changes in symptom burden measured by MDASI symptom scale(6 and 12 months)
- Clinical outcomes(At baseline)
- Patient experiences measured at PREM(6 and 12 months)
- Clinical outcome(Baseline, 6 and 12 months)
- Clinical medication(Baseline)